Clinical trials · San Francisco, CA
Hepatocellular Carcinoma (HCC) clinical trials in San Francisco
We’re tracking 15 recruiting hepatocellular carcinoma (hcc) studies with a site in or near San Francisco — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near San Francisco
- NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other solid tumors
This trial tests an oral drug called TYRA-430 for people with advanced liver cancer (HCC) or other solid tumors that have changes in the FGF/FGFR pathway. It aims to see how safe the drug is and whether it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT02081755Enrolling by invitationPhase 4
Everolimus after liver transplant to lower liver cancer return
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
San Francisco, CaliforniaAges 18 years+ - NCT06084234RecruitingPhase 4
National liver cancer screening trial
This trial is testing a new way to screen for liver cancer in people with cirrhosis or chronic hepatitis B. It aims to find cancer earlier so it can be treated more effectively.
San Francisco, CaliforniaAges 18–85 - NCT04430452RecruitingPhase 2
Durvalumab with or without tremelimumab after liver radiation
This study tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help control hepatocellular carcinoma (liver cancer) after you receive palliative, targeted radiation. It especially focuses on people whose cancer continued to grow after, or without, certain prior immune therapies.
San Francisco, CaliforniaAges 18 years+ - NCT04134559RecruitingPhase 2
Pembrolizumab for kids with liver cancer that came back
This trial studies pembrolizumab (an immune therapy) in children and young people with hepatocellular carcinoma (HCC) that has returned or did not respond to earlier treatment. The goal is to see whether it can shrink tumors and help control the cancer.
San Francisco, CaliforniaAges birth–30 years - NCT04510129Recruiting
Cancer biospecimen collection study for immunotherapy patients
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
San Francisco, CaliforniaAges 18 years+ - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
San Francisco, CaliforniaAges 1–21 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
San Francisco, CaliforniaAges 1–30 - NCT07166406RecruitingPhase 3
Immunotherapy with or without targeted radiation for advanced liver cancer
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
San Francisco, CaliforniaAges 18 years+ - NCT07303712Recruiting
Liquid Biopsy for Liver Cancer After Y90 Treatment
This study uses a simple blood test (called a liquid biopsy) to learn more about your liver cancer after you receive a targeted radiation treatment called Y90 radioembolization. The goal is to see if the blood test can help doctors better understand how the cancer responds to treatment.
Palo Alto, CaliforniaAges 18 years+ - NCT05486572Recruiting
Ultrasound or MRI to help prevent liver cancer deaths
This study compares ultrasound scans versus MRI scans to see which one better helps prevent deaths from liver cancer in people with cirrhosis. You may be assigned to one of the two imaging tests and follow-up visits to track whether liver cancer develops or is caught early.
Palo Alto, CaliforniaAges 18–75 - NCT06921785RecruitingPhase 3
Combination therapy for first-line liver cancer treatment
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
Palo Alto, CaliforniaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Palo Alto, CaliforniaAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Stanford, CaliforniaAges 18 years+
Hear when a new Hepatocellular Carcinoma (HCC) trial opens near San Francisco, CA
We’ll email you when one opens near San Francisco, CA — at most once a week, no account needed, unsubscribe anytime.
Hepatocellular Carcinoma (HCC) trials in other cities
Where these studies are running near San Francisco
Institutions with a site for the recruiting hepatocellular carcinoma (hcc) studies listed above.
- University of California, San Francisco · 6 studies
- Stanford University · 2 studies
- VA Palo Alto Health Care System · 2 studies
- Alta Bates Summit Medical Center
- California Pacific Medical Center
- Curebase
- Exelixis Clinical Site #123
- Lucile Packard Children's Hospital at Stanford
What taking part in a hepatocellular carcinoma (hcc) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting hepatocellular carcinoma (hcc) studies in California.
Common questions
- Are there hepatocellular carcinoma (hcc) clinical trials near San Francisco?
- Yes. We're currently tracking 15 recruiting hepatocellular carcinoma (hcc) studies with a site near San Francisco, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hepatocellular carcinoma (hcc) study near San Francisco?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in San Francisco to take part?
- Not necessarily. These studies have a site near San Francisco, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hepatocellular carcinoma (hcc) studies open near San Francisco regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.